While the stem-cell capacity of RUNX1-FPD patients has yet to be evaluated, MDS HSPCs exhibit similarly poor ex vivo growth and poor engraftment in immunodeficient mice (20). The gene discussed is RUNX1; the disease is myelodysplastic syndrome.